Literature DB >> 10411781

The intrauterine contraceptive device: an often-forgotten and maligned method of contraception.

K L Dardano1, R T Burkman.   

Abstract

Although 90% of women at risk for unintended pregnancy in the United States use contraception, <1% of these women use the intrauterine contraceptive device. The mechanism of action of intrauterine contraceptive devices has been controversial, but several studies suggest that interference with sperm migration or function and with fertilization may be the most likely mechanisms. More important, there is lack of compelling evidence that the intrauterine contraceptive device acts as an abortifacient. The risk for pelvic inflammatory disease among users now appears to be extremely low, primarily as a result of better selection of candidates. A levonorgestrel-releasing intrauterine contraceptive device may offer some new therapeutic approaches for the treatment of certain gynecologic disorders. Although women who are not at risk for pelvic inflammatory disease or sexually transmitted diseases are appropriate candidates for the intrauterine contraceptive device, it appears that use can be expanded to selected nulliparous women and women with certain medical conditions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411781     DOI: 10.1016/s0002-9378(99)70426-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

Review 1.  In the patient's best interest? Revisiting sexual autonomy and sterilization of the developmentally disabled.

Authors:  H H Pham; B H Lerner
Journal:  West J Med       Date:  2001-10

2.  Barriers to contraceptive use in product labeling and practice guidelines.

Authors:  Daniel Grossman; Charlotte Ellertson; Katrina Abuabara; Kelly Blanchard; Francisco T Rivas
Journal:  Am J Public Health       Date:  2006-01-31       Impact factor: 9.308

Review 3.  Tranexamic acid: a review of its use in the management of menorrhagia.

Authors:  Keri Wellington; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.